You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨綠葉製藥(2186.HK)一度衝高至9% 瑞欣妥®在華重磅獲批
格隆匯 01-14 15:41
格隆匯1月14日丨綠葉製藥(2186.HK)尾盤一度漲至9%,報3.84港元,暫成交1.24億港元,總市值124.76億港元。綠葉製藥午間宣佈,注射用利培酮微球(II)(LY03004,瑞欣妥®)已獲中國國家藥品監督管理局批准上市。瑞欣妥®為注射用緩釋微球製劑,是綠葉製藥基於其全球領先的新型長效製劑技術平台開發的新藥,是中國首個自主研發、開展全球註冊的、具有自主知識產權的創新微球製劑。該產品的專利在中國、美國、歐洲、日本、韓國、俄羅斯、加拿大、澳大利亞均獲得授權,專利期至2032年。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account